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ABSTRACT
Cancer cells reprogram cellular metabolism to meet the demands of growth. 
Identification of the regulatory machinery that regulates cancer-specific metabolic 
changes may open new avenues for anti-cancer therapeutics. The epigenetic 
regulator BRG1 is a catalytic ATPase for some mammalian SWI/SNF chromatin 
remodeling enzymes. BRG1 is a well-characterized tumor suppressor in some human 
cancers, but is frequently overexpressed without mutation in other cancers, including 
breast cancer. Here we demonstrate that BRG1 upregulates de novo lipogenesis 
and that this is crucial for cancer cell proliferation. Knockdown of BRG1 attenuates 
lipid synthesis by impairing the transcription of enzymes catalyzing fatty acid and 
lipid synthesis. Remarkably, exogenous addition of palmitate, the key intermediate 
in fatty acid synthesis, rescued the cancer cell proliferation defect caused by BRG1 
knockdown. Our work suggests that targeting BRG1 to reduce lipid metabolism and, 
thereby, to reduce proliferation, has promise for epigenetic therapy in triple negative 
breast cancer.
INTRODUCTION
Upregulation of lipogenic genes and overall 
lipogenesis are hallmarks of cancer [1]. Depending on the 
tumor type, tumor cells synthesize up to 95% of saturated 
and mono-unsaturated fatty acids (FA) de novo despite 
sufficient exogenous supply [2]. Lipogenic enzymes such 
as fatty acid synthase (FASN), acetyl-CoA carboxylase 
(ACC), and ATP citrate lyase (ACLY) that are involved 
in fatty acid biosynthesis and sterol regulatory element 
binding protein 1 (SREBP1), the master regulator of 
lipogenic gene expression, are overexpressed in a number 
of cancers including breast, prostate, ovarian, lung, 
and colon [3–6]. Several lines of evidence suggest that 
activation of the de novo fatty acid synthesis pathway 
is required for carcinogenesis [1, 7, 8]. For example, 
elevated levels of FASN, the major enzyme responsible 
for fatty acid biosynthesis, are correlated with poor 
prognosis in breast cancer patients [1, 7]. Increases in 
both FASN expression and activity are observed early in 
oncogenesis and correlate with cancer progression, with 
FASN-overexpressing tumors exhibiting more aggressive 
phenotypes [1]. Chemical or RNAi-mediated inhibition of 
key enzymes involved in fatty acid synthesis, including 
FASN, ACC and ACLY, reduces cell proliferation, induces 
apoptosis of cancer cells and retards the growth of human 
tumors in mouse xenograft models [1, 9–13]. 
Whereas various tumor types display increased 
endogenous fatty acid biosynthesis irrespective of 
extracellular lipid availability, most normal cells, even 
those with comparatively high proliferation rates, 
preferentially use dietary/exogenous lipids for synthesis of 
new structural lipids [1, 12]. We sought to investigate how 
lipogenic pathways are re-wired in cancer. Mammalian 
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SWI/SNF complexes are evolutionarily conserved, 
multisubunit enzymes that mobilize nucleosomes and 
remodel chromatin using the energy of ATP hydrolysis 
[14–16]. These enzymes are important in DNA 
replication and repair, cell growth control, maintenance of 
pluripotency, and promotion of cell lineage differentiation. 
Increasing evidence supports an important role for human 
SWI/SNF enzyme subunits in cancer development 
[17, 18]. Meta-analyses of cancer genome-sequencing 
data estimates that nearly 20% of human cancers harbor 
mutations in one or more SWI/SNF genes [17–20]. We 
and others reported that knockdown of BRG1 reduces 
cell proliferation in both breast epithelial and cancer cells 
in vitro [21–23] and attenuates tumor growth in a xenograft 
model [21, 22]. However, the underlying mechanisms 
remained unknown. Here we report that BRG1 directly 
regulates triple negative breast cancer cell proliferation via 
regulation of lipogenic pathways. Knockdown of BRG1 
decreased de novo lipid synthesis in breast cancer cells, but 
not in breast epithelial cells, with concomitant reduction in 
cell proliferation. BRG1 knockdown significantly reduced 
lipogenic gene expression. Chromatin immunoprecipitation 
analysis revealed that BRG1 was bound to sequences at 
lipogenic genes. Re-introducing BRG1 largely restored 
FASN and ACC expression, de novo lipid synthesis and 
cell proliferation. Supplementing the cell media with 
exogenous palmitate completely restored cell proliferation 
in BRG1 knockdown cells, thereby demonstrating a causal 
link between lipid synthesis and cancer cell proliferation 
and identifying a novel mechanism by which lipogenic 
signaling is crucial for cancer cell growth. 
RESULTS 
Reduction of BRG1 in cancer cells attenuated  
de novo lipid synthesis
One of the most conserved features of all cancers 
is the reprogramming of cellular metabolism in favor of 
biosynthetic processes that support high proliferation 
rates and survival in the tumor microenvironment [24]. 
To support unlimited growth, cancer cells exhibit higher 
rates of glucose metabolism, protein synthesis and de novo 
lipid synthesis [25, 26]. We surveyed these pathways by 
metabolic labeling in MDA-MB-231 triple negative breast 
cancer cells in the presence of a scrambled sequence 
shRNA or shRNA targeting BRG1 [21, 22, 27]. Glucose 
uptake and protein synthesis were not affected in MDA-
MB-231 BRG1 knockdown cells (Figure 1A–1C). 
Interestingly, de novo lipid synthesis was reduced by 40% 
in the MDA-MB-231 BRG1 knockdown cells (Figure 1D) 
but not in MCF-10A breast epithelial cells expressing the 
same shRNA against BRG1 (Figure 1E). Western blot 
analysis confirmed the knockdown of BRG1 in both cell 
lines (Figure 1F). This observation was reproduced in 
other triple negative breast cancer lines (MDA-MB-468 
and HDQ-P1) that were treated with a previously validated 
pool of siRNAs targeting BRG1 [22, 27] (Figure 1G–1H). 
ADAADi (Active DNA-dependent ATPase A Domain 
inhibitor), a minor product generated by the bacterial APH 
(3′)-III enzyme that encodes for aminoglycoside resistance, 
inhibits the ATPase activity of the SWI2/SNF2 family of 
ATPases [28, 29] and increases the chemosensitivity of 
triple negative breast cancer cells to clinically relevant 
therapeutic drugs [30]. Pharmacological inhibition of 
the BRG1 ATPase domain by ADAADi in MDA-MB-
231cells also decreased de novo lipid synthesis (Figure 1I). 
Collectively, the data show a role for BRG1 in promoting 
de novo lipid synthesis in triple negative breast cancer cells.
BRG1 upregulates lipogenic gene expression in 
triple negative breast cancer cells
The reduction in de novo lipid synthesis in BRG1 
knockdown breast cancer cells was directly caused by 
reduction of lipogenic gene expression. De novo fatty-
acid synthesis involves two key enzymes, ACC and FASN. 
ACC carboxylates acetyl-CoA to form malonyl-CoA, and 
the malonyl-CoA product is subsequently converted by 
FASN to palmitate, a precursor for longer-chain fatty acids 
[31]. As shown in Figure 2A, mRNA levels of ACC and 
FASN were down-regulated after BRG1 knockdown in 
breast cancer cells but not in non-tumorigenic MCF-10A 
mammary epithelial cells. The protein levels of these 
enzymes were also reduced by BRG1 knockdown in 
breast cancer cells, but not in non-tumorigenic MCF-10A 
mammary epithelial cells (Figure 2B). 
The expression of other genes involved in the 
synthesis or metabolism of lipids was also regulated by 
BRG1 (Figure 2C). Elevated glucose catabolism produces 
an excess of the glycolytic end-product, pyruvate. Most 
excess pyruvate is converted to lactate, but some is 
converted to acetyl-CoA by ATP citrate lyase (ACLY) and 
can be used in de novo fatty-acid synthesis. Therefore, 
ACLY is the link between the metabolism of carbohydrates 
and the production of fatty acids and represents an 
important step in fatty acid biosynthesis [32]. Long-
chain acyl CoA synthetase (ACSL) catalyzes the first step 
in fatty acid activation for intracellular metabolism by 
converting long-chain fatty acids into acyl-CoA thioesters 
[33, 34]. ACSL1 is the best-studied and the major ACSL 
isoform, is highly expressed in major energy-metabolizing 
tissues, and plays a key role in lipid biosynthesis and fatty 
acid degradation [35]. Lipin-1 (LPIN1) is a magnesium-
dependent phosphatidic acid phosphohydrolase that 
catalyzes the penultimate step in triglyceride synthesis 
including the dephosphorylation of phosphatidic acid to 
yield diacylglycerol [36]. The expression of all these genes 
was decreased by BRG1 knockdown (Figure 2C).
We next showed that BRG1 directly bound to 
these genes having BRG1-dependent expression. We 
predicted BRG1 binding sites based on BRG1 ChIP-seq 
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Figure 1: BRG1 knockdown reduced de novo lipid synthesis in triple negative breast cancer cells but not in MCF-10A 
mammary epithelial cells. (A) MDA-MB-231 cells expressing either a scrambled sequence shRNA or an shRNA targeting BRG1 
were incubated with 14C-glucose and incorporation of radioactivity into cells was measured to determine glucose uptake. There was no 
significant change. (B) BRG1 knockdown cells also had no change in the rate of protein synthesis compared to control cells as measured 
by 3H-leucine incorporation. (C) Phosphorimage of the blot of  35S-labeled protein extracted from control and BRG1 knockdown cells (left) 
and Coomassie brilliant blue staining of the blot (right). (D) BRG1 knockdown cells had a decrease in de novo lipid synthesis as measured 
by 14C-acetate incorporation in total extracted lipids. (E) MCF-10A cells expressing a scrambled sequence shRNA or shRNA targeting 
BRG1 were incubated with 14C-acetate and incorporation of radioactivity into extracted total lipids was measured. BRG1 knockdown did 
not cause a significant decrease in lipid synthesis. (F) Western blot analysis verified the shRNA-mediated knockdown of BRG1 in MDA-
MB-231 and MCF-10A cells. (G) Western blot analysis verified the siRNA-mediated knockdown of BRG1 in MDA-MB-468 and HDQ-P1 
cells. (H) Three triple negative breast cancer cell lines were treated with scrambled sequence siRNA or a cocktail of siRNAs targeting 
BRG1 and 14C-acetate incorporation into extracted total lipids was measured. (I) A small molecule inhibitor (ADAADi) of BRG1 inhibited 
de novo lipid synthesis in MDA-MB-231 cells. Each data point represents the mean of 3 independent experiments performed in triplicate. 
Error bars are standard deviations. ***P < 0.001. 
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data from K562 and HeLa cells and global H3K27Ac 
and DNase I hypersensitivity analyses [37] and used 
these for PCR primer design within the region 1.5 Kb 
upstream of the TSS of the ACC, FASN, ACLY and 
ACSL1 genes (Supplementary Figure 1). There were 
no active transcriptional marks in sequences upstream 
of the LPIN1 TSS, however, there were multiple active 
marks in the first intronic region of this gene, allowing 
the design of PCR primers in this region (Supplementary 
Figure 1). Chromatin immunoprecipitation (ChIP) analysis 
detected BRG1 binding at these lipogenic genes in control 
cells that was markedly decreased in BRG1 knockdown 
cells (Figure 2D). Additional ChIP controls are shown in 
Supplementary Figure 2. These data suggest that BRG1 
directly and transcriptionally regulates lipid biosynthesis 
and metabolism pathways in these breast cancer cells.
Reduction in de novo lipid synthesis impaired 
cancer cell proliferation
To further confirm that BRG1 is the direct cause 
for the reduction in lipid biosynthesis, a complementary 
experiment was performed to restore BRG1 expression in 
the knockdown cells. Re-expression or over-expression 
of wildtype or catalytically inactive BRG1 is negligible 
in some cell types if Brahma (BRM), the closely related 
ATPase that can act as the catalytic subunit in mammalian 
SWI/SNF complexes in a manner that is mutually exclusive 
with BRG1, is expressed [38–40]. In addition, we have 
previously shown that knockdown of either BRG1 or 
BRM in triple negative breast cancer cell lines results in 
increased expression of the remaining ATPase [22] and 
that both BRG1 and BRM contribute to triple negative 
cell proliferation [30]. Therefore we re-established BRG1 
expression in MDA-MB-231 cells after expressing 
shRNA against both BRG1 and BRM [22] by transient 
transfection with plasmid vectors. Re-expression of 
BRG1 in this double knockdown background resulted in 
increasing levels of FASN and in a dose-dependent manner 
(Figure 3A), as well as a concomitant increase in de novo 
lipid synthesis (Figure 3B). As we previously reported [22], 
re-expression of BRG1 in double knockdown cells caused 
only a partial rescue in cell proliferation (Figure 3C). This 
is expected since we have shown that BRM also contributes 
to cell proliferation [30]. These data show that BRG1 
regulates both de novo lipid synthesis and cell proliferation. 
Figure 2: BRG1 was required for the expression of genes involved in fatty acid and lipid synthesis. (A) mRNA levels 
of ACC and FASN in MDA-MB-231 and MCF-10A cells expressing either a scrambled sequence shRNA or an shRNA targeting BRG1 
were measured by qPCR. (B) Western blot analysis measuring protein levels of ACC and FASN in MDA-MB-231 and MCF-10A cells 
expressing a scrambled sequence shRNA or shRNA targeting BRG1. (C) mRNA levels of ACLY, ACSL1 and LPIN1 in MDA-MB-231 
cells expressing either a scrambled sequence shRNA or an shRNA targeting BRG1 were determined by qPCR. (D) ChIP experiments 
with MDA-MB-231 cells expressing either a scrambled sequence shRNA or an shRNA targeting BRG1 demonstrated that BRG1 binds 
to sequences upstream of each gene. Negative control sequences 1 and 2 are within the coding sequences of the ACC and FASN genes, 
respectively. Each dataset represents the mean of 3 independent experiments performed in triplicate. Error bars are standard deviations. 
**P < 0.01, ***P < 0.001.
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We reasoned that, as an upstream regulator of 
key lipogenic enzymes, depletion of BRG1 should also 
increase the sensitivity of cells to fatty acid synthesis 
inhibitors. 5-tetradecyloxy-2-furoic acid (TOFA) is an 
inhibitor of ACC [41]. When TOFA was added to cells, 
the decrease in viable cell number was larger after 
BRG1 knockdown than in control cells (Figure 4A). 
The FASN inhibitor c75 [42] decreased cell viability in 
control cells, underscoring the need for de novo lipid 
biogenesis in highly proliferative tumor cells. As shown 
in Figure 4B, c75 potency was significantly enhanced in 
BRG1 knockdown cells compared to control cells. ACC 
and FASN have been reported to be essential to cancer 
cell survival, and knocking down either ACC or FASN 
dramatically decreases cancer cell proliferation [9, 43, 44]. 
After reducing BRG1 levels, breast cancer cells showed 
increased sensitivity to both inhibitors. 
Since the end product of FASN and common 
intermediate in all de novo fatty acid synthesis is 
palmitate, we asked if the decrease in palmitate production 
was responsible for the impaired cell proliferation in 
cancer cells with BRG1 knockdown [22]. Following 
BRG1 knockdown, the cell culture medium was replaced 
with medium containing increasing doses of nonfat 
BSA-conjugated palmitic acid, and cell proliferation was 
measured. As shown in Figure 4C, addition of exogenous 
palmitic acid in the culture medium completely rescued the 
cell proliferation defect in BRG1 knockdown cells but had 
no effect on control cells. This result shows that BRG1-
dependent contributions to de novo lipid synthesis in turn 
regulate the rate of the breast cancer cell proliferation.
Addition of palmitate did not affect ACC or FASN 
expression in either control of BRG1 knockdown cells 
(Figure 4D). Thus BRG1 function is upstream of ACC and 
FASN expression, which is upstream of palmitate production 
and de novo lipid synthesis, which are upstream of cell 
proliferation. The data do not exclude possible feedback 
signals whereby the altered proliferation rate also affects 
de novo lipid synthesis. Regardless, the results demonstrate 
that decreased cell proliferation in BRG1 knockdown cells 
can be attributed to the decrease in expression of the key 
metabolic enzymes for fatty acid synthesis. 
Figure 3: Restoration of BRG1 expression in cells depleted for BRG1 partially rescued the decrease in de novo 
lipid synthesis and cell proliferation. (A) Western blot analysis showing that re-expression of BRG1 partially restored ACC and 
FASN protein levels. (B) Re-expression of BRG1 partially reversed the inhibition of de novo lipid synthesis caused by loss of BRG1. 
(C) Re-expression of BRG1 partially reversed the inhibition of cell growth caused by loss of BRG1. Each dataset represents the mean of 
3 independent experiments performed in triplicate. Error bars are standard deviations. *P < 0.05, **P < 0.01, ***P < 0.001. 
Oncotarget38275www.impactjournals.com/oncotarget
DISCUSSION
One of the hallmarks of cancer is elevated de novo 
fatty acid synthesis [45]. Clinical and basic scientific 
investigation has shown that human cancers synthesize 
fatty acids via the de novo fatty acid synthesis pathway 
even when exogenous fatty acids are abundant, seemingly 
independent of the regulatory signals that control fatty-
acid synthesis in normal cells. The role of FASN in 
normal human biology includes energy storage from 
excess carbohydrates to fat in liver and adipose tissue 
and specialized functions that facilitate lactation in the 
breast and reproduction in endometrium and decidua 
[46–48]. FASN expression during these processes is 
strictly regulated by nutrition and hormonal levels [49]. 
In contrast, FASN is highly expressed in many cancers 
and precancerous lesions. In this context, the expression 
of FASN is independent of nutrition, and in many cases, it 
appears independent of hormonal regulation [45]. Despite 
its promise as a target for anti-cancer therapeutics [1, 12, 
50, 51], the mechanism by which FASN is dysregulated 
in cancer is unknown. Similarly, two enzymes catalyzing 
rate limiting steps upstream of FASN in de novo fatty 
acid synthesis, ACC and ACLY, are often dysregulated 
in cancer and have been proposed as breast cancer 
therapeutic targets [52–54].
BRG1 is a known epigenetic regulator of chromatin 
structure and gene expression that may also play an 
architectural role in gene organization [55]. We show 
here that loss of BRG1 attenuated FASN, ACC, and 
ACLY expression and impaired de novo lipid synthesis 
in breast cancer cells with a concomitant decrease in cell 
proliferation. Importantly, this phenomenon was only 
seen in cancer cells and not in non-tumorigenic mammary 
epithelial cells. Re-introducing BRG1 to BRG1- and 
BRM-depleted cancer cells increased FASN and ACC 
expression, increased de novo lipid synthesis, and partially 
restored cell proliferation. When the culture medium was 
Figure 4: Fatty acid levels regulated breast cancer cell proliferation. (A–B) BRG1 knockdown rendered cells more sensitive to 
growth inhibition by the ACC inhibitor TOFA or the FASN inhibitor c75. (C) Addition of palmitic acid to the cell culture media completely 
reversed the growth inhibition caused by BRG1 knockdown. (D) Addition of palmitic acid did not affect FASN or ACC expression in 
control or in BRG1 knockdown cells. Each dataset represents the mean of 3 independent experiments performed in triplicate. Error bars are 
standard deviations. *P < 0.05, ***P < 0.001, n.s. not significant. 
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supplemented with palmitic acid, the end product of FASN 
and the key intermediate in the synthesis of longer chain 
and desaturated fatty acids, cell proliferation in BRG1 
knockdown cells was completely rescued. The complete 
rescue in cells where only BRG1 was knocked down 
and BRM was present suggests that BRG1 is the SWI/
SNF ATPase predominantly responsible for regulation 
of these metabolic pathways. Thus our results provide 
the first evidence of a direct relationship between BRG1, 
lipogenic enzyme transcriptional control, de novo fatty 
acid synthesis, and cell proliferation. 
We and others have demonstrated that BRG1 levels 
are elevated in primary breast cancer [22, 23]. Our results 
here show that the elevated levels of lipid synthesis 
found in breast cancer are dependent on BRG1 acting 
to upregulate the transcription of FASN, ACC, ACLY 
and other genes involved in fatty acid synthesis. BRG1 
is therefore an epigenetic link between breast cancer cell 
proliferation and fatty acid synthesis, but it is likely to be 
only the first factor identified in a novel regulatory circuit 
up-regulating lipogenic enzyme expression in cancer with 
downstream consequences on cell proliferation. Further 
investigation of BRG1 and the BRG1-interacting factors 
of this circuit will elucidate mechanisms by which cancer 
cells rewire signaling pathways controlling de novo lipid 
biosynthesis. 
Strategically targeting BRG1 for cancer therapy 
BRG1 function in cancer appears to be context 
dependent. It is mutated in lung and other cancers [56, 57], 
and cancers featuring loss of the SNF5/INI1 subunit may 
require BRG1 [18], thereby suggesting the potential of 
targeting BRG1 to treat such tumors [58, 59]. In addition, 
BRG1 is upregulated with little evidence of mutation in 
primary breast and prostate tumors, in melanoma and 
neuroblastoma, and in pancreatic, gastric, and colorectal 
carcinomas [22, 23, 60–67]. Therefore, developing 
small molecule inhibitors that interfere with BRG1 
function or that fine-tune the expression of BRG1 back 
to physiological levels might provide therapeutic benefits. 
Indeed, we have recently demonstrated that knockdown of 
BRG1 or use of a BRG1 inhibitor sensitizes triple negative 
breast cancer cells to commonly used chemotherapeutic 
agents, perhaps via modulation of ABC transporter 
expression [30].
The data presented here show that BRG1 is 
specifically required for fatty acid and lipid synthesis in 
triple negative breast cancer cells but not in mammary 
epithelial cells. This specificity increases the promise for 
BRG1- based therapies in triple negative breast cancer 
compared to treatment approaches that non-specifically 
target fatty acid and lipid synthesis. We conclude 
that targeting BRG1 and its cooperating factors are a 
promising and novel strategy for attacking both cancer cell 
proliferation and cancer metabolism. 
MATERIALS AND METHODS
Cell culture
MCF-10A cells from the Karmanos Cancer Institute 
(Detroit, MI) were maintained in monolayer as described 
[68]. MDA-MB-231 cells were obtained from T. Guise 
[69]. MCF-10A cells inducibly expressing shRNA targeting 
BRG1 or a control shRNA were previously described [21]. 
MDA-MB-231 cells inducibly expressing shRNA targeting 
BRG1, BRG1 + BRM, or a control shRNA were previously 
described [22]. MDA-MB-468 cells were obtained from 
Professor Hong Zhang (UMass Medical School). HDQ-P1 
cells were purchased from the Leibniz Institute DSMZ-
German Collection of Microorganisms and Cell Culture 
(Braunschweig, Germany). MDA-MB-231, MDA-MB-468 
and HDQ-P1 cells were maintained in DMEM containing 
10% FBS and Penicillin/Streptomycin. Doxycycline-
inducible knockdown was performed as described [21, 
22, 27] using 500 ng/ml doxycycline for MCF-10A cells 
and 100 ng/ml doxycycline for MDA-MB-231 cells. 
siRNA-mediated knockdown of BRG1 was performed 
using the validated pool of siRNAs and methods described 
previously [22, 27]. 
The identities of the breast cancer cell lines were 
authenticated by Short Tandem Repeat profiling at the 
Genetic Resources Core Facility, Johns Hopkins School of 
Medicine, Institute of Genetic Medicine. MCF-10A cells 
were similarly authenticated at the University of Vermont 
Cancer Center.
Reagents
Doxycycline, palmitic acid, TOFA, c75, MTT (3-(4, 
5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide), 
and anti-GAPDH antibody were purchased from Sigma 
(Sigma-Aldrich, St. Louis, MO). FASN (C20G5) and acetyl-
CoA carboxylase (C83B10) antibodies were purchased from 
Cell Signaling (Cell Signaling Technology, Inc., Danvers, 
MA, USA). Anti-rabbit and anti-mouse IgG, and HRP-linked 
antibodies were from GE (GE Healthcare Life Science, 
Pittsburgh, PA, USA). BRG1 antiserum [70] was used in 
western blot and ChIP experiments. The BRM antibody 
(ab15597) used in western blots was purchased from Abcam 
(Cambridge, MA, USA). D-14C-Glucose, 3H-Leucine, 
35S-Methionine and [2–14C] acetic acid were purchased from 
PerkinElmer (PerkinElmer Life Sciences, Waltham, MA, 
USA). ADAADi was prepared as described [28].
Proliferation assays
Five thousand cells were seeded in each well of 
96-well plates, and treated as indicated in each figure 
legend the following day. MTT solution at a final 
concentration of 5 ug/mL was added to each well and 
samples were incubated for 4 hours. The media was 
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subsequently removed and the plates were air-dried. One 
hundred microliters of DMSO were added to each well and 
incubated for 30 minutes at room temperature with gentle 
shaking. Absorbance was measured at OD540 in a Synergy 
H4 Hybrid microplate reader (Bio Tek, Winooski, VT).
Glucose uptake assay
Cells were pulse labeled with 1 μCi 14C-glucose for 
5 minutes, and then washed 3 times with PBS. Cells were 
trypsinized and counted. One million cells were lysed by 
adding 200μL 0.2N NaOH for 15 min. The cell lysate were 
transferred to a scintillation vial, and radioactive signal 
was measured in a scintillation counter (Beckman Coulter 
LS6500). 
Protein synthesis assays
Protein synthesis rate was determined by labeling 
cells with 1 μCi 3H-Leucine for 4 h. After three washes 
in ice cold PBS, cells were lysed with PBS containing 
2% SDS before scintillation counting. All readings were 
normalized by cell number determined from parallel 
plates. For other protein synthesis assays, cells were 
labeled with 10 μCi 35S-Methionine overnight, washed 
3 times with ice cold PBS, and then lysed with PBS 
containing 1% NP-40. Radiolabeled proteins (2 µg) were 
run on SDS-PAGE 4–20% gradient gels before transfer 
to a PVDF membrane. Radioactivity was measured by 
Phosphoimager and checked for equal protein loading by 
staining the membrane with Coomassie Brilliant Blue. 
De novo lipid synthesis assay
In experiments with ADAADi, cells were pre-
treated with 2 μM ADAADi for 48 h prior to addition 
of radiolabeled acetate. Breast cancer cells were labeled 
with 1 μCi /mL 14C-acetate for 1 h. MCF-10A cells were 
labeled with 5 μCi /mL 14C acetate for 1 h. After removal 
of the labeling medium, cells were washed 3 times with 
PBS and then cultured in fresh medium for 24 h. At the 
end of the incubation, cells were trypsinized and counted. 
One million cells were used for lipid extraction. Total 
lipids were extracted as described [71], transferred to a 
scintillation vial and counted in a scintillation counter 
(Beckman Coulter LS6500). 
c75, TOFA and palmitic acid treatment
MDA-MB-231 SCRAM and shBRG1 cells were 
plated in 96-well plates at a density of 3,000 cells/well and 
treated with 0.1 μg/ml doxycycline or with vehicle for 48 
h. Reagents were added to the cell culture medium at 0, 15, 
or 20 nM for 24 h (palmitic acid) or at 10, 25, or 50 μM 
for 72 h (c75, TOFA). To assess cell proliferation, 10 µL 
of MTT reagent was added to each well and incubated for 
4 h prior to an MTT assay.
Western blotting
Cells were washed, trypsinized, and counted and 
whole cell lysates from one million cultured cells were 
prepared by lysis in 200 μL of 1× Laemmli sample buffer 
and boiled for 5 min. 10 μL of lysate was separated 
on SDS-polyacrylamide gels (4–20% gradient) and 
transferred to PVDF membrane. Membranes were 
blocked in 5% non-fat dry milk in PBS, incubated with 
primary antibodies overnight at 4oC. Following repeated 
washing in 5% milk/PBS, membranes were incubated 
with secondary antibody conjugated to HRP for 1 hour at 
room temperature, washed repeatedly with 5%milk/PBS, 
and developed using Amersham ECL Western Blotting 
Detection Reagents and Amersham Hyperfilm ECL (GE 
LifeScience). 
RT-qPCR
One million cells were used for extraction of 
total RNA using RNeasy Plus following manufacturer’s 
instructions (Qiagen Inc., Valencia, CA, USA). cDNA 
synthesis was accomplished using a SuperScript III kit 
(Invitrogen, San Diego, CA, USA). Gene expression was 
measured by real time qPCR using following primers. ACC 
alpha (ACACA) forward 5′-ATGCG GTCTATCCGTAGG- 
3′, reverse 5′-GGTGTGACCATGA CAAC-3′; FASN, 
forward 5′-GTTTGATGCCTCCTTCTTC-3′, reverse 
5′-CGGAG TG AATCTGGGTTG-3′; ACLY forward 
5′- CCCAAGTCCAAGATCCCTGC-3′, reverse 5′- 
TCGTCTCGG GAGCAGACATA-3′; ACSL1 forward 
5′- GGAAGAGCCAACAGA CGGAA-3′, reverse 5′- 
CATTGCTCCTTTGGGGTTGC-3′; LPIN1 forward 
5′- GAGGCAGAC AGCACCATACA-3′, reverse 5′- 
GGCTAACTGCCCCACGTAAT-3′.
Chromatin immunoprecipitation (ChIP)
ChIP was performed as described previously 
[38] with modifications. Cells were cooled to room 
temperature before crosslinking which was done by 
replacing the media with ice-cold growth medium 
containing 3.7% formaldehyde for 40 min at 4ºC. 
Each ChIP reaction used 5 μg of BRG1 antiserum 
[70] or control IgG (Millipore, Billerica, MA) and 50 
μg of chromatin extract. Primers used for measuring 
BRG1 binding at those promoters measured by qPCR 
are listed below: ACC alpha (ACACA), forward 5′- 
GTCCCACCCCGTAAGGATTT -3′ (-537 ~ -556 bp to 
TSS), reverse 5′- GGCGCTAGCTCCAAACTAAC -3′ 
(-708~-727 bp to TSS); 
FASN, forward 5′- CTCCCGAGTGATTCCTCGAA 
-3′(-1086 ~ -1105 bp to TSS), reverse 5′- CTCAAAGT 
AGGACACGCAGC -3′ (-1233 ~ -1252 bp to TSS); 
ACLY, forward 5′- GTAAGCAAGTGGGGCTAGG 
AG -3′ (-570 ~ -590 bp to TSS), reverse 5′CTTCGCT 
GGAATCTCGCATTG -3′ (-665~ -684 bp to TSS); 
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ACSL1, forward 5′- CCAGACTGCCTCGGA 
TTTCATA -3′ (-130 ~ -151 bp to TSS), reverse 5′- 
GGCGGTCCAATGTACCCTT
-3′ (-172 ~ -191 bp to TSS); 
LIPIN1, forward 5′-TGCAGCCCATTTCCTGG 
ATT-3′ (+66,769 bp ~ +66,788 bp to TSS), reverse 
5′-GAGGAAGGAGGGGCTGAGTA-3′ (+66,842 bp ~ 
(+66,861 bp to TSS).
Genomic region (chr17:35,716,490-35,716,996) 
near the ACACA promoter was used as a negative 
control for BRG1 binding, forward 5′-ATACATGC 
TGGATCCTGGCG-3′, reverse 5′-GGACGGGAAGCA 
TTCTCCAA-3′. Genomic region (chr17:80,055,818-
80,056,106) near the FASN promoter served as an 
additional negative control for BRG1 binding, forward 
5′-CTCCGAAGGGGCACGAAC-3′, reverse 5′-TCCTC 
ATCCTCCGCTCTCG-3′. Meanwhile, ABCC3 gene 
expression was not affected by depletion of BRG1 
in our previous work [30]. Therefore BRG1 binding 
at this locus was used to serve additional negative 
control, with primer sequences as following: forward 5′- 
ATTCAGGAGGGAGCTTTGCC-3′ (+4,555 bp ~ +4,754 
bp to TSS), reverse 5′- CCATTTCCCTGTCTGGGGAC- 
3′(+4,589 bp ~ +4,608 bp to TSS). RNase polymerase II 
binding at this locus was used as positive control in the 
ChIP experiment.
Statistical analyses
Quantified data represent the mean of three 
independent experiments performed in triplicate with 
standard deviation (S.D). Statistical relevance was 
evaluated using GraphPad Instat two-tail P value student 
test (Graphpad Software, Inc., La Jolla, CA).
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